

Lana McClements

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4746681/publications.pdf>

Version: 2024-02-01

50
papers

1,194
citations

361296

20
h-index

414303

32
g-index

57
all docs

57
docs citations

57
times ranked

1468
citing authors

#	ARTICLE	IF	CITATIONS
1	Increased complications of COVID-19 in people with cardiovascular disease: Role of the renin-angiotensin-aldosterone system (RAAS) dysregulation. <i>Chemico-Biological Interactions</i> , 2022, 351, 109738.	1.7	33
2	Impact of reduced uterine perfusion pressure model of preeclampsia on metabolism of placenta, maternal and fetal hearts. <i>Scientific Reports</i> , 2022, 12, 1111.	1.6	9
3	The diagnostic potential of oxidative stress biomarkers for preeclampsia: systematic review and meta-analysis. <i>Biology of Sex Differences</i> , 2022, 13, .	1.8	9
4	Role of A Novel Angiogenesis FKBPL-CD44 Pathway in Preeclampsia Risk Stratification and Mesenchymal Stem Cell Treatment. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 26-41.	1.8	28
5	The importance of polymorphisms of regulatory and catalytic antioxidant proteins in chronic kidney disease. <i>Medicinski Podmladak</i> , 2021, 72, 25-33.	0.2	0
6	GSTM1 Modulates Expression of Endothelial Adhesion Molecules in Uremic Milieu. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-12.	1.9	5
7	Extracellular Vesicles from Mesenchymal Stromal Cells for the Treatment of Inflammation-Related Conditions. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3023.	1.8	27
8	Simple-to-Operate Approach for Single Cell Analysis Using a Hydrophobic Surface and Nanosized Droplets. <i>Analytical Chemistry</i> , 2021, 93, 4584-4592.	3.2	16
9	3D Bioprinted cancer models: Revolutionizing personalized cancer therapy. <i>Translational Oncology</i> , 2021, 14, 101015.	1.7	90
10	Considerations to Model Heart Disease in Women with Preeclampsia and Cardiovascular Disease. <i>Cells</i> , 2021, 10, 899.	1.8	7
11	Characterisation of cardiac health in the reduced uterine perfusion pressure model and a 3D cardiac spheroid model, of preeclampsia. <i>Biology of Sex Differences</i> , 2021, 12, 31.	1.8	12
12	NOVEL MIRNAS AS TARGETS OF MESENCHYMAL STEM CELLS-BASED THERAPY FOR TREATMENT OF PREECLAMPSIA. <i>Journal of Hypertension</i> , 2021, 39, e26-e27.	0.3	0
13	FKBPL and SIRT-1 Are Downregulated by Diabetes in Pregnancy Impacting on Angiogenesis and Endothelial Function. <i>Frontiers in Endocrinology</i> , 2021, 12, 650328.	1.5	20
14	Stem cell-based approaches in cardiac tissue engineering: controlling the microenvironment for autologous cells. <i>Biomedicine and Pharmacotherapy</i> , 2021, 138, 111425.	2.5	33
15	Plasma Amino Acids Metabolomics' Important in Glucose Management in Type 2 Diabetes. <i>Frontiers in Pharmacology</i> , 2021, 12, 695418.	1.6	24
16	Evaluation of the diagnostic accuracy of current biomarkers in heart failure with preserved ejection fraction: A systematic review and meta-analysis. <i>Archives of Cardiovascular Diseases</i> , 2021, 114, 793-804.	0.7	10
17	The influence of uremic serum and GSTM1 knockdown on redox homeostasis in HUVECs. <i>Free Radical Biology and Medicine</i> , 2021, 177, S82-S83.	1.3	0
18	Non-viral gene delivery utilizing RALA modulates sFlt-1 secretion, important for preeclampsia. <i>Nanomedicine</i> , 2021, 16, 1999-2012.	1.7	2

#	ARTICLE	IF	CITATIONS
19	Engaging hard-to-reach populations in research on health in pregnancy: the value of Boalâ€™s simultaneous dramaturgy. <i>Arts and Health</i> , 2020, 12, 71-79.	0.6	0
20	FKBPL-based peptide, ALM201, targets angiogenesis and cancer stem cells in ovarian cancer. <i>British Journal of Cancer</i> , 2020, 122, 361-371.	2.9	38
21	Mechanisms of Key Innate Immune Cells in Early- and Late-Onset Preeclampsia. <i>Frontiers in Immunology</i> , 2020, 11, 1864.	2.2	102
22	FKBPL is associated with metabolic parameters and is a novel determinant of cardiovascular disease. <i>Scientific Reports</i> , 2020, 10, 21655.	1.6	17
23	054 Potential New Treatment Based on FKBPL for Hypertension-Induced Cardiac Hypertrophy. <i>Heart Lung and Circulation</i> , 2020, 29, S62.	0.2	0
24	FKBPL, a novel player in cardiac ischaemia and fibrosis. <i>Journal of Molecular and Cellular Cardiology</i> , 2020, 140, 5.	0.9	2
25	Can Stem Cells Beat COVID-19: Advancing Stem Cells and Extracellular Vesicles Toward Mainstream Medicine for Lung Injuries Associated With SARS-CoV-2 Infections. <i>Frontiers in Bioengineering and Biotechnology</i> , 2020, 8, 554.	2.0	49
26	Top Notch Targeting Strategies in Cancer: A Detailed Overview of Recent Insights and Current Perspectives. <i>Cells</i> , 2020, 9, 1503.	1.8	92
27	Mechanisms of heart failure with preserved ejection fraction in the presence of diabetes mellitus. <i>Translational Metabolic Syndrome Research</i> , 2020, 3, 1-5.	0.2	4
28	Emerging Therapeutic Potential of Mesenchymal Stem/Stromal Cells in Preeclampsia. <i>Current Hypertension Reports</i> , 2020, 22, 37.	1.5	28
29	Overlapping pathogenic signalling pathways and biomarkers in preeclampsia and cardiovascular disease. <i>Pregnancy Hypertension</i> , 2020, 20, 131-136.	0.6	19
30	Association of Nrf2, SOD2 and GPX1 Polymorphisms with Biomarkers of Oxidative Distress and Survival in End-Stage Renal Disease Patients. <i>Toxins</i> , 2019, 11, 431.	1.5	24
31	Markers of Oxidative Stress and Endothelial Dysfunction Predict Haemodialysis Patients Survival. <i>American Journal of Nephrology</i> , 2019, 50, 115-125.	1.4	19
32	Service evaluation of diabetes management during pregnancy in a regional maternity hospital: potential scope for increased self-management and remote patient monitoring through mHealth solutions. <i>BMC Health Services Research</i> , 2019, 19, 662.	0.9	18
33	Association between Galectin-3 levels within central and peripheral venous blood, and adverse left ventricular remodelling after first acute myocardial infarction. <i>Scientific Reports</i> , 2019, 9, 13145.	1.6	9
34	FKBPL and its peptide derivatives inhibit endocrine therapy resistant cancer stem cells and breast cancer metastasis by downregulating DLL4 and Notch4. <i>BMC Cancer</i> , 2019, 19, 351.	1.1	45
35	Hypercapnic acidosis induces mitochondrial dysfunction and impairs the ability of mesenchymal stem cells to promote distal lung epithelial repair. <i>FASEB Journal</i> , 2019, 33, 5585-5598.	0.2	34
36	An Integrative Biomedical Informatics Approach to Elucidate the Similarities Between Pre-Eclampsia and Hypertension. <i>Studies in Health Technology and Informatics</i> , 2019, 264, 988-992.	0.2	3

#	ARTICLE	IF	CITATIONS
37	Risk of pre-eclampsia in women taking metformin: a systematic review and meta-analysis. <i>Diabetic Medicine</i> , 2018, 35, 160-172.	1.2	70
38	4...The role of a novel anti-angiogenic protein, FKBPL, in angiogenesis associated with cardiac dysfunction. , 2018, , .		0
39	6...The role of a novel angiogenesis related protein, FKBPL, in spiral uterine artery remodelling important for the pathogenesis of preeclampsia. , 2018, , .		0
40	MESENCHYMAL STEM CELLS INFLUENCE TROPHOBLAST AND ENDOTHELIAL CELL FUNCTIONALITY IMPORTANT FOR PREVENTION OF PRE-ECLAMPSIA VIA A NOVEL ANTI-ANGIOGENIC PROTEIN, FKBPL. <i>Journal of Hypertension</i> , 2018, 36, e154.	0.3	1
41	Abstract LB-054: FKBPL as a novel therapeutic target and prognostic biomarker in high grade serous ovarian cancer. , 2018, , .		0
42	Elucidating the Pathogenesis of Pre-eclampsia Using In Vitro Models of Spiral Uterine Artery Remodelling. <i>Current Hypertension Reports</i> , 2017, 19, 93.	1.5	44
43	FKBPL Is a Critical Antiangiogenic Regulator of Developmental and Pathological Angiogenesis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 845-854.	1.1	38
44	RALA-mediated delivery of FKBPL nucleic acid therapeutics. <i>Nanomedicine</i> , 2015, 10, 2989-3001.	1.7	57
45	FKBPL: a marker of good prognosis in breast cancer. <i>Oncotarget</i> , 2015, 6, 12209-12223.	0.8	13
46	The Role of Peptidyl Prolyl Isomerases in Aging and Vascular Diseases. <i>Current Molecular Pharmacology</i> , 2015, 9, 165-179.	0.7	16
47	Identification of RBCK1 as a novel regulator of FKBPL: implications for tumor growth and response to tamoxifen. <i>Oncogene</i> , 2014, 33, 3441-3450.	2.6	31
48	Targeting Treatment-Resistant Breast Cancer Stem Cells with FKBPL and Its Peptide Derivative, AD-01, via the CD44 Pathway. <i>Clinical Cancer Research</i> , 2013, 19, 3881-3893.	3.2	63
49	The Anti-Migratory Effects of FKBPL and Its Peptide Derivative, AD-01: Regulation of CD44 and the Cytoskeletal Pathway. <i>PLoS ONE</i> , 2013, 8, e55075.	1.1	30
50	Editorial: New Technologies for Women's Health. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 10, .	2.0	0